Literature DB >> 29477389

An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].

Louis P Garrison1, Mark V Pauly2, Richard J Willke3, Peter J Neumann4.   

Abstract

The second section of our Special Task Force builds on the discussion of value and perspective in the previous article of the report by 1) defining a health economics approach to the concept of value in health care systems; 2) discussing the relationship of value to perspective and decision context, that is, how recently proposed value frameworks vary by the types of decisions being made and by the stakeholders involved; 3) describing the patient perspective on value because the patient is a key stakeholder, but one also wearing the hat of a health insurance purchaser; and 4) discussing how value is relevant in the market-based US system of mixed private and public insurance, and differs from its use in single-payer systems. The five recent value frameworks that motivated this report vary in the types of decisions they intend to inform, ranging from coverage, access, and pricing decisions to those defining appropriate clinical pathways and to supporting provider-clinician shared decision making. Each of these value frameworks must be evaluated in its own decision context for its own objectives. Existing guidelines for cost-effectiveness analysis emphasize the importance of clearly specifying the perspective from which the analysis is undertaken. Relevant perspectives may include, among others, 1) the health plan enrollee, 2) the patient, 3) the health plan manager, 4) the provider, 5) the technology manufacturer, 6) the specialty society, 7) government regulators, or 8) society as a whole. A valid and informative cost-effectiveness analysis could be conducted from the perspective of any of these stakeholders, depending on the decision context.
Copyright © 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cost-effectiveness analysis; decision context; perspective; value

Mesh:

Year:  2018        PMID: 29477389     DOI: 10.1016/j.jval.2017.12.006

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  29 in total

1.  Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time.

Authors:  Gemma E Shields; Becky Pennington; Ash Bullement; Stuart Wright; Jamie Elvidge
Journal:  Pharmacoeconomics       Date:  2021-12-06       Impact factor: 4.981

2.  Family Spillover Effects: Are Economic Evaluations Misrepresenting the Value of Healthcare Interventions to Society?

Authors:  Ashley A Leech; Pei-Jung Lin; Brittany D'Cruz; Susan K Parsons; Tara A Lavelle
Journal:  Appl Health Econ Health Policy       Date:  2022-08-23       Impact factor: 3.686

3.  Patient-Proxy and Societal Perspectives of Quality-of-Life Utilities in Children With Cleft Lip and Palate Managed With Surgical Repair vs No Repair in Ethiopia.

Authors:  Karen Y Chung; Gebremedhin B Gebretekle; Andrew Howard; Eleanor Pullenayegum; Mekonen Eshete; Christopher R Forrest; Beate Sander
Journal:  JAMA Netw Open       Date:  2022-07-01

4.  Costs of multimorbidity: a systematic review and meta-analyses.

Authors:  Phuong Bich Tran; Joseph Kazibwe; Georgios F Nikolaidis; Ismo Linnosmaa; Mieke Rijken; Josefien van Olmen
Journal:  BMC Med       Date:  2022-07-19       Impact factor: 11.150

Review 5.  Hip protectors are cost-effective in the prevention of hip fractures in patients with high fracture risk.

Authors:  R T A L de Bot; H D Veldman; A M Witlox; L W van Rhijn; M Hiligsmann
Journal:  Osteoporos Int       Date:  2020-02-10       Impact factor: 4.507

6.  Economic Evaluation in Opioid Modeling: Systematic Review.

Authors:  Elizabeth Beaulieu; Catherine DiGennaro; Erin Stringfellow; Ava Connolly; Ava Hamilton; Ayaz Hyder; Magdalena Cerdá; Katherine M Keyes; Mohammad S Jalali
Journal:  Value Health       Date:  2020-10-26       Impact factor: 5.725

7.  Direct costs of adhering to selected Duchenne muscular dystrophy Care Considerations: Estimates from a midwestern state.

Authors:  Kristin M Conway; Scott D Grosse; Lijing Ouyang; Natalie Street; Paul A Romitti
Journal:  Muscle Nerve       Date:  2022-02-09       Impact factor: 3.852

8.  Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.

Authors:  Simon de Montigny; Blythe J S Adamson; Benoît R Mâsse; Louis P Garrison; James G Kublin; Peter B Gilbert; Dobromir T Dimitrov
Journal:  Sci Rep       Date:  2018-04-17       Impact factor: 4.379

9.  Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018.

Authors:  David D Kim; Madison C Silver; Natalia Kunst; Joshua T Cohen; Daniel A Ollendorf; Peter J Neumann
Journal:  Pharmacoeconomics       Date:  2020-10       Impact factor: 4.981

10.  The Importance of Collaboration in Pursuit of Patient-Centered Value Assessment.

Authors:  Mark T Linthicum; Susan dosReis; Julia F Slejko; T Joseph Mattingly; Jennifer L Bright
Journal:  Patient       Date:  2021-07       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.